Medical Device News Magazine

Launch of Apex Laser Series, the World’s First and Only High-Powered Multi-Wavelength Laser for Photobiomodulation

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Launch of Apex Laser Series is the newest addition to the premium Aspen Laser family, positioning it ahead of the market as a flagship solution in photobiomodulation (laser therapy) reports Aspen Laser Systems.

The Apex Tri-Wave Laser model is the world’s first and only therapy laser that features three therapeutic wavelengths: 810nm, 980nm and 1064nm, each with the capability of operating at a max power of 15 watts and a combined total output of 45 watts.

With this new product launch, Aspen Laser introduces the 1064nm wavelength to the US market. The 1064nm wavelength is a longer wavelength that can penetrate deeper into tissue. Clinical studies indicate that it has the least dispersion within biological tissues due to its decreased melanin absorption. The result is deep activation of metabolic processes vital for all cellular activities.

The Apex Laser Series allows healthcare practitioners a new and effective clinical tool to deliver optimal outcomes. This new model combines exclusive high average power PowerDose diodes and advanced Wavelength MultiPlexer Technology to provide the broadest range and selections of therapeutic wavelengths. In addition to the Apex Tri-Wave 45 watt model, the Apex Laser Series includes a Dual-Wave Laser model option featuring 60 watts of total output with 30 watts each of 810nm and 1064nm (or 980nm) wavelengths. The Apex Dual-Wave Laser model is also the only one of its kind in the world.

“The Apex Laser Series is surpassing the results that we originally planned for,” said Charles Vorwaller, CEO of Aspen Laser Systems, LLC. “This product has been in research and development for the past two years, and because of the broad range of power, wavelengths and operating mode choices, it is a wonderful support for our Patient Response Driven Clinical Protocols. This means a healthcare professional will have significantly better outcomes and physiological effects that include increased circulation, reduced inflammation, pain reduction and enhanced tissue healing. The Apex Laser Series is a great addition for any healthcare professional, whether experienced or just starting out with photobiomodulation.”

Photobiomodulation is a non-invasive and painless treatment used to treat pain and inflammation from conditions such as arthritis, tendonitis, and acute joint or muscle injuries, and the treatment can be applied to both humans and animals. Instead of just treating symptoms that may provide temporary benefits, photobiomodulation is a superior treatment option because it provides energy to cells that trigger a chemical response resulting in the body to heal itself.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”